BPC-157 + TB-500 co-formulation — wholesale research blend

For research use only · Not for human consumption · Not for veterinary use. This product is supplied for in-vitro research, analytical method development, and laboratory reference standard use only. Not approved for human or veterinary administration. Buyer is responsible for end-use classification in the destination jurisdiction.

Overview

The BPC-157 + TB-500 co-formulation is a pre-blended research compound supplied as a single lyophilized vial containing two independently verified peptide components at a defined mass ratio. BPC-157 is a 15-amino-acid synthetic peptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val), and TB-500 is a 44-amino-acid synthetic fragment of Thymosin β4. Each component is verified by HPLC and mass spectrometry independently before blending, and the final blended vial carries a multi-component Certificate of Analysis that documents the per-component purity, the per-vial quantitation, and the blending ratio. SPK Pharma India supplies the BPC-157 + TB-500 blend as a research convenience SKU, intended for in-vitro cell-based assays, tissue repair pathway research, and analytical method development.

Specifications

Research context

BPC-157 and TB-500 are independently studied in regenerative pathway research. BPC-157 is a 15-amino-acid peptide studied in cell-based assays of nitric oxide pathway dynamics, growth factor signalling, and tissue repair pathway components. TB-500, as a Thymosin β4 fragment, is studied in cell-based assays of actin sequestration, cell migration, and tissue regeneration pathway components. The co-formulation is supplied for research contexts where the two compounds are run in parallel in the same assay plate, eliminating the per-vial reconstitution and per-component dilution steps that would otherwise be required.

The blending ratio is defined at the time of compounding and is documented on the multi-component COA. The compound is also supplied at custom ratios on request, for research programmes that require non-standard combinations. SPK Pharma India does not make therapeutic, clinical, diagnostic, or dosing claims for this product. The compound is supplied strictly for in-vitro research, analytical method development, and reference-standard work.

For researchers new to the compound, the standard analytical reference points are the per-component CAS numbers, the per-component sequences, the lyophilized powder form, and the documented per-component purity threshold (≥99% HPLC). The full per-component amino acid sequences are disclosed on the lot-matched COA and on the product specification sheet.

Packaging and supply

• 5 mg + 5 mg blend vial — for method development, parallel cell-based assays, and reference-standard qualification. Standard MOQ: 5 vials.
• 10 mg + 10 mg blend vial — for ongoing research programmes with higher per-assay demand. Standard MOQ: 2 vials.
• Custom ratio — on application, with the specific ratio and per-component mass documented on the COA.

Distributor pricing is available on application. Annual supply contracts with scheduled recurring dispatch are available for repeat buyers. Lead time for in-stock SKUs is typically 5 business days from purchase order confirmation; lead time for scheduled production is typically 4 to 6 weeks.

Quality and documentation

Every lot of the BPC-157 + TB-500 blend ships with a multi-component lot-matched Certificate of Analysis documenting per-component identity (mass spectrometry and amino acid analysis), per-component purity (HPLC, verified before blending), per-vial quantitation, blending ratio, lot number, and synthesis batch reference. A representative sample of every lot is independently verified by a third-party analytical laboratory before release. MSDS is supplied with every shipment. The COA template, the lot-traceability workflow, and the third-party verification scope are documented on the Quality page.

Storage and handling

• Store at -20°C in the original sealed container.
• Protect from light and moisture.
• Allow the sealed container to reach room temperature before opening, to avoid condensation.
• Reconstitute in sterile, low-endotoxin research-grade water or in a mild buffer at the working concentration required by the assay.
• Do not refreeze once reconstituted; aliquot and store at working concentration.
• Avoid vigorous vortexing; allow gentle dissolution to minimise aggregation.

Shipping

The BPC-157 + TB-500 blend is shipped lyophilized in sealed vials within temperature-validated packaging. International lanes are routed through dedicated life-science logistics partners with cold-chain handling. Standard dispatch is within 5 business days of purchase order confirmation. SPK Pharma India ships to the United States, the European Union, the United Kingdom, Canada, MENA, APAC, and LATAM. Full export documentation, including commercial invoice, packing list, certificate of origin, COA, and MSDS, is included with every shipment. Destination-specific documentation is supported on request.

Compliance

This product is supplied for research use only. It is not a drug, not a finished dosage form, and not approved for human or veterinary administration. SPK Pharma India does not make therapeutic, clinical, diagnostic, or dosing claims for this product. The buyer is responsible for end-use classification in the destination jurisdiction and for ensuring that downstream handling is consistent with research-use-only protocols.

Lead form CTA

To request a wholesale quote for the BPC-157 + TB-500 co-formulation, contact the trade desk with the subject line "BPC-TB blend wholesale quote" and your company details, expected volume, and destination country. Distributor pricing is available on application. The desk responds within one business day.

Related compounds

• BPC-157 + TB-500 + GHK-Cu (3-peptide blend) — extended co-formulation
• BPC-157 + TB-500 + GHK-Cu + KPV (4-peptide blend) — full 4-peptide research blend
• GHK-Cu — copper tripeptide research compound
• Cartalax — BPC-157 derivative research peptide
• PEG-MGF — pegylated mechano growth factor research peptide